Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stanley Schwartz, Benjamin A Kohl
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/d23891c3616d47fcbaad20237dd3bb80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d23891c3616d47fcbaad20237dd3bb80
record_format	dspace
spelling	oai:doaj.org-article:d23891c3616d47fcbaad20237dd3bb802021-12-02T01:03:24ZType 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies1178-7007https://doaj.org/article/d23891c3616d47fcbaad20237dd3bb802010-07-01T00:00:00Zhttp://www.dovepress.com/type-2-diabetes-mellitus-and-the-cardiometabolic-syndrome-impact-of-in-a4817https://doaj.org/toc/1178-7007Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates of type 2 diabetes mellitus, obesity, and cardiovascular disease (CVD) continue to increase at epidemic proportions. It has become clear that these disease states are not independent but are frequently interrelated. By addressing conditions such as obesity,&shy; &shy;insulin resistance, stress hyperglycemia, impaired glucose tolerance, and diabetes &shy;mellitus, with its micro- and macrovascular complications, a specific treatment strategy can be &shy;developed. These conditions can be addressed by early identification of patients at high risk for type 2 diabetes, prompt and aggressive treatment of their hyperglycemia, recognition of the pleiotropic and synergistic benefits of certain antidiabetes agents on CVD, and thus, avoiding potential complications including hypoglycemia and weight gain. Incretin-based therapies, which include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have the potential to alter the course of type 2 diabetes and associated CVD complications. Advantages of these therapies include glucose-dependent enhancement of insulin secretion, infrequent instances of hypoglycemia, weight loss with GLP-1 receptor agonists, weight maintenance with DPP-IV inhibitors, decreased blood pressure, improvements in dyslipidemia, and potential beneficial effects on CV function.Keywords: cardiovascular disease, glucose control, GLP-1 receptor agonists, DPP-IV inhibitors Stanley SchwartzBenjamin A KohlDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 227-242 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Stanley Schwartz Benjamin A Kohl Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
description	Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates of type 2 diabetes mellitus, obesity, and cardiovascular disease (CVD) continue to increase at epidemic proportions. It has become clear that these disease states are not independent but are frequently interrelated. By addressing conditions such as obesity,&shy; &shy;insulin resistance, stress hyperglycemia, impaired glucose tolerance, and diabetes &shy;mellitus, with its micro- and macrovascular complications, a specific treatment strategy can be &shy;developed. These conditions can be addressed by early identification of patients at high risk for type 2 diabetes, prompt and aggressive treatment of their hyperglycemia, recognition of the pleiotropic and synergistic benefits of certain antidiabetes agents on CVD, and thus, avoiding potential complications including hypoglycemia and weight gain. Incretin-based therapies, which include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have the potential to alter the course of type 2 diabetes and associated CVD complications. Advantages of these therapies include glucose-dependent enhancement of insulin secretion, infrequent instances of hypoglycemia, weight loss with GLP-1 receptor agonists, weight maintenance with DPP-IV inhibitors, decreased blood pressure, improvements in dyslipidemia, and potential beneficial effects on CV function.Keywords: cardiovascular disease, glucose control, GLP-1 receptor agonists, DPP-IV inhibitors
format	article
author	Stanley Schwartz Benjamin A Kohl
author_facet	Stanley Schwartz Benjamin A Kohl
author_sort	Stanley Schwartz
title	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_short	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_full	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_fullStr	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_full_unstemmed	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
title_sort	type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/d23891c3616d47fcbaad20237dd3bb80
work_keys_str_mv	AT stanleyschwartz type2diabetesmellitusandthecardiometabolicsyndromeimpactofincretinbasedtherapies AT benjaminakohl type2diabetesmellitusandthecardiometabolicsyndromeimpactofincretinbasedtherapies
_version_	1718403346235129856

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

Ejemplares similares